The current human clinical classification scheme for PH groups disorders with related pathologic and hemodynamic findings and similar therapeutic responses. 2 Broadly, there are 5 major categories:
Group I, pulmonary arterial hypertension (PAH); Group 2, PH caused by left-sided heart disease; Group 3, PH caused by chronic lung disease or hypoxemia; Group 4, chronic thromboembolic PH; and Group 5, PH with unclear multifactorial mechanisms. 2 Although these categories of PH have been adapted for use in dogs, 1 the number of diseases within each category is much smaller, either because the parallel condition does not occur in dogs or because it has not yet been recognized. Recently, pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) in dogs were recognized, and histologic features detailed; 3 both of these conditions are considered a subset of Group I disorders leading to PH in humans.
The hallmark feature of PVOD is occlusive remodeling of small and medium pulmonary veins, leading to upstream congestion of alveolar capillaries and pulmonary arterial remodeling. 3, 4 PCH is an angioproliferative disorder characterized by proliferation of alveolar capillaries, which may infiltrate into pulmonary veins and arteries as well as bronchioles. 5 In humans with PVOD, 75% have concurrent lesions of PCH, leading to speculation that they may be part of the same disease spectrum. [6] [7] [8] Regardless, both are rare causes of PAH that can be challenging to discriminate from other causes of PH. However, in humans, this discrimination is important as PVOD and PCH carry a grave prognosis and treatment for PAH with vasodilators can lead to acute deterioration and death from severe pulmonary edema. 9, 10 Given the paucity of veterinary literature on occlusive vascular diseases leading to PH, the main objective of our study was to report the clinical characteristics (signalment, historical clinical signs, physical examination findings, and diagnostic testing), treatments, and outcome of dogs with a histologic diagnosis of PVOD or PCH.
Although a detailed histologic description of 11 of the dogs in our study has been previously published, 3 knowledge of the clinical presentation of PVOD and PCH in dogs will help increase suspicion for these syndromes, improve diagnosis and prognostication, and ultimately could promote future studies evaluating treatment interventions and investigation of underlying genetic or environmental triggers.
| MATERIALS AND METHODS
For our retrospective study, the sole inclusion criterion was histologic Thoracic radiographic evaluation was based on previously described methods. 11, 12 When radiographs from multiple time points
were available for a patient, the last set of radiographs were used for scoring evaluation. Briefly, increased pulmonary opacity was classified as unstructured interstitial, alveolar, or mixed interstitial/alveolar pattern. Distribution of pulmonary changes was classified as diffuse when all lungs were involved, focal when a single area of lung was involved or multifocal if multiple areas of lung were involved.
Localization of focal or multifocal pulmonary patterns was determined as craniodorsal, cranioventral, caudodorsal, or caudoventral depending on the quadrant of lung involved on lateral projections.
Pulmonary pattern was considered symmetric if the left and right lungs were equally affected, asymmetric otherwise. Size of the cardiac silhouette was evaluated subjectively. Blood vessel diameters were evaluated. Cranial lung lobe pulmonary vessels were considered normal if diameters were less than the width of the proximal one-third of the 4th rib. 11, 13 Caudal pulmonary vessels were normal if diameters were less than the width of the 9th rib where they crossed. 11, 13 Blood vessels were considered tortuous if any deviation from their expected course was identified. The presence of pleural fissures was recorded.
Thoracic CT images obtained from all 3 dogs at the University of Missouri were performed using a standardized protocol of inspiratory and expiratory breath holds with the assistance of a mechanical ventilator (Engstrom Carestation ventilator; GE Healthcare, Fairfield, CT).
The volume-controlled ventilation setting was used, and tidal volume was set to 10 mL/kg, inspired oxygen at 40% and positive end- 
| Statistical methods
Because of the retrospective nature of our study and small sample size, data were analyzed descriptively, and when appropriate, the median and range were reported. 
| Diagnostic testing
Limited hematologic data were available in a subpopulation of dogs using a variety of analyzers. Hematocrit was above the reference range in 3 of 11 dogs (56%, 60%, and 69%) for which values were recorded. The median hematocrit in 11 dogs was 52%, range 32%-69%, and in 7 dogs, the median neutrophil count was 11 900/μL (range 6200-16 080/μL). Hypoalbuminemia was reported in 9 dogs with a median of 2.5 g/dL (range 1.8-2.6 g/dL). Other abnormalities included increased (n = 3) or decreased (n = 1) blood urea nitrogen, decreased globulins (n = 3), increased creatinine (n = 2), increased alanine aminotransferase (n = 2), increased alkaline phosphatase (n = 2), and increased total bilirubin (n = 1). Urine specific gravity was 1.015 in a single dog that had a concurrent urine protein to creatinine ratio of 2.4. (all with at least some degree of PCH) and PCH alone in 1 dog.
| DISCUSSION
In the dog, PVOD and PCH represent 2 newly described vaso-occlusive disorders leading to severe PH, respiratory compromise, and ultimately, death. An acute onset of respiratory distress is a sequel to many disorders of the cardiopulmonary system; however, in the context of thoracic radiographic evidence of enlarged pulmonary arteries and an interstitial or alveolar pattern, PVOD and PCH should be differentials. The cases represented herein had a rapid progression with a median survival of 3 days after presentation, likely corresponding to advanced remodeling lesions of the pulmonary vasculature. In human medicine, PVOD and PCH generally have a more insidious onset with progressive disease, although sudden death has been reported. tive means to diagnose PVOD and PCH and many interstitial lung diseases; it is also useful when the other aforementioned less invasive diagnostics have failed to reveal a definitive answer. Importantly, the risk of thoracotomy and biopsy needs to be carefully weighed against benefit of definitive diagnosis, and the goal is to identify a treatable underlying lung disease, so that it can be effectively managed.
One of the most common causes of PH in dogs is left-sided heart failure, generally caused by myxomatous mitral valve disease (MMVD). [26] [27] [28] This disorder predominantly occurs in small breed dogs, with PH developing as a continuum of heart disease progressing to heart failure. 26 An emergent presentation of a small breed dog in respiratory distress, with a left-sided systolic heart murmur, radiographic evidence of cardiac enlargement and pulmonary edema, and increased PAP would almost certainly be caused by MMVD. However, increased PAP in the absence of left-sided heart failure requires consideration of other differential diagnoses, including canine PVOD and PCH. Although to a certain degree all diseases associated with PH in dogs are generally considered to have a poor prognosis, 1 there is still marked variation in outcomes and survival. For example, one study in dogs with MMVD with PH documented a median survival time of 456 days. 26 In contrast, 10 of 15 (66%) dogs in our study survived less than 1 day.
All the dogs in our study were adults older than 8 years of age (median 11 years), which is in contrast to humans with PVOD who are predominantly young to middle-aged, although affected ages range from infancy to older than 70 years old. 6, 7, 17, 19 Failure to identify PVOD and PCH in puppies and young to middle-aged dogs may be due to the lack of recognition, not the lack of the absence of these conditions, and deserves further study. There was no sex or breed predilection identified, perhaps, because of the small number of dogs FIGURE 5 Postmortem image of the lungs from the 9-year-old female-spayed Goldendoodle with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis (PCH). The lungs failed to fully collapse upon loss of negative intrathoracic pressure and contain numerous, often coalescing superficial red foci that correspond to histologic evidence of the angiomatous lesions of PCH. These foci also corresponded to ground glass opacity nodules on the computed tomography scan FIGURE 4 Nine-year-old female-spayed Goldendoodle with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Computed tomography transverse image displayed in a lung window taken at the level of the caudal thorax demonstrating marked multifocal ground-glass opacification characterized nodular opacities (white arrows) of variable size and located in a random fashion throughout the parenchyma. Complete opacification suggesting atelectasis, consolidation or hemorrhage was consistently visible in the dependent aspect of the lungs in this dog (asterisk) in our study. Most dogs were of larger body size with multiple breeds affected. In humans, a genetic risk for PVOD and PCH has been documented. [29] [30] [31] [32] Aside from heritable genetic mutations, known predisposing factors for PVOD in humans include chemotherapeutics, exposure to organic solvents, bone marrow or stem cell transplants, neoplasia, connective tissue disorders/autoimmune diseases, sarcoidosis, HIV infection, and pulmonary Langerhans cell histiocytosis (reviewed in References 6, 7, and 10). In comparison, there are no clear-cut risk factors for PCH aside from genetic factors. 6 Because of the retrospective and multi-institutional nature of our study, putative exposures leading to canine PVOD or PCH were not assessed.
Results of complete blood counts, serum biochemical profiles, and urinalyses were generally nonspecific, and abnormalities could have been due to comorbid conditions. Development of polycythemia (27%; 3/11 dogs) is considered a chronic change and might suggest a more protracted clinical course than was suggested by their owners. Hypoxemia was noted in all dogs in which it was measured, consistent with reports in humans. 6, 19 Echocardiography frequently revealed evidence of changes to the right side of the heart, consistent with increased workload caused by remodeled and occluded pulmonary vessels.
Although not all dogs received an echocardiographic examination, for the 7 dogs that did, there was direct or indirect evidence of PH. Ancillary testing aimed at identifying underlying cardiac and respiratory disorders failed to reveal an antemortem diagnosis. Airway lavage was misleading in 1 dog with evidence of a yeast and bacterial infection that ultimately led to lung biopsy. In 2 other dogs, hemosiderosis was a notable finding. Chronic alveolar hemorrhage from engorgement of fragile pulmonary capillaries leads to hemosiderin-laden macrophages in airway lavage and sputum of humans with PVOD and PCH. 8, 18, 33, 34 Congestive heart failure is another differential for hemosiderincontaining pulmonary macrophages 35 potentially adding confusion to the diagnostic evaluation of a dog with acute onset of respiratory distress, PAH, and radiographic changes supportive of pulmonary edema.
Of note, based on histopathologic examination of the lung, several of the dogs in this report were initially diagnosed with congestive heart failure; use of special stains to highlight and differentiate pulmonary arteries and pulmonary veins was required for definitive diagnosis. In humans with idiopathic PAH, in addition to dilatation of the central, right, and left main pulmonary arteries and right-sided cardiac changes, the presence of tortuous corkscrew-like peripheral pulmonary arteries reflects the hallmark plexogenic arteriopathy lesions. 14 While sharing dilatation of the pulmonary arteries and pathology of the right chambers of the heart, CT lesions of PVOD and PCH have other unique features including centrilobular GGO. 39 Centrilobular GGO reflect increased capillary blood volume, thickening of interstitial tissues, airspace fluid accumulation, and alveolar collapse. 40, 41 In humans with PVOD, widespread smooth thickening of interlobular septa in combination with centrilobular GGO helps to discriminate these conditions from other causes of PH. 42 On a microscopic level in human PVOD, occluded interlobular septal veins are reflected by CT evidence of interlobular septal thickening; centrilobular GGO are caused by upstream congestion of capillaries, concurrent lesions of PCH, or both. 8 In PCH, discrete areas of capillary proliferation can cause widespread poorly circumscribed centrilobular GGO; typically, this occurs without interlobular septal thickening, as the interlobular septal veins are unaffected. 8 In humans, larger centrilobular GGO nodules are seen with PCH compared with PVOD. 39 As dogs lack interlobular septa and secondary pulmonary lobules, interlobular pathology as seen in humans is not noted and the term "centrilobular" is not an appropriate descriptor. However, 2 dogs in our study having CT scans had GGO in a location analogous to the centrilobular position, which were similarly sized and equally distant from each other. The 3rd dog had more random distribution of GGO nodules. 8, 34 Oral administration of sildenafil to a cat with PCH-like disease was speculated to cause acute massive pulmonary edema that ultimately contributed to death. 38 Adverse response to vasodilators is not always immediate, with one study of 24 human cases of PVOD showing 9 days as the median time from the start of treatment to development of pulmonary edema (range, 1-240 days).
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Of interest, a retrospective study using sildenafil for 13 dogs with PH (of which an underlying cause of PH was not determined in 5 cases and was deemed "idiopathic"), 3 dogs were euthanized with a day of initiating treatment because of severe respiratory distress. 43 It would be tempting to speculate that these dogs could have had PVOD or PCH. Although in the current study PAPs decreased in the 2 dogs treated with pulmonary vasodilators with the longest survivals, there were 3 dogs treated with sildenafil that were euthanized within 1-2 days. Thus it may be inappropriate to assume that vasodilators are harmful in these dogs as they are in humans, and further studies will be needed to draw conclusions about the role of vasodilators in management of canine PVOD or PCH.
The only definitive treatment for PVOD or PCH in humans is lung transplantation. Otherwise, as in dogs, these are fatal diseases. A presumptive diagnosis of PVOD or PCH based on clinical presentation, echocardiography, imaging (in particular CT scans), and other ancillary tests as deemed relevant provides important prognostic information about this grave condition, with most dogs dying within days of presentation regardless of attempted treatment. It is presently unknown if pulmonary vasodilators are harmful or helpful in these dogs, in contrast to the use of these medications for canine PH secondary to MMVD, non-cardiogenic pulmonary edema, and chronic respiratory diseases. 26, 36, 43, 44 In conclusion, awareness of PVOD and PCH in dogs as newly described vaso-occlusive disorders causing severe PAH will be required for future investigation of genetic or environmental triggers and optimal treatment strategies. Given the striking similarities in clinicopathologic features, histologic characteristics, and grave outcome shared with human PVOD and PCH, these disorders have relevance for one health.
